Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T-2 relaxometry pilot study
Stephen J Wood, Luca Cocchi, Tina-Marie Proffitt, Mirabel McConchie, Graeme D Jackson, Tsutomu Takahashi, Christos Pantelis, Patrick D McGorry, Gregor E Berger
PSYCHIATRY RESEARCH-NEUROIMAGING | ELSEVIER IRELAND LTD | Published : 2010
We used magnetic resonance imaging to examine the effect of ethyl-eicosapentaenoic acid (E-EPA) on hippocampal T(2) relaxation time in first episode psychosis patients at baseline and after 12 weeks of follow-up. There was an increase in T(2) in the placebo group but not in the E-EPA group, suggesting a neuroprotective effect of E-EPA treatment. In addition, the smaller the increase in T(2), the greater the improvement in negative symptoms.
Related Projects (1)
Awarded by NHMRC
Awarded by Swiss National Science Foundation
This work was supported by two NH&MRC project grants (ID. 145627; 209062), a NH&MRC program grant (ID: 350241), and the Colonial Foundation, Melbourne, Australia A/Prof Wood is supported by a Clinical Career Development Award from the NH&MRC, and Dr Cocchi by a Swiss National Science Foundation young investigator award (PBLAB3-119622). A Margaret & Walter Lichtenstein Foundation award (University of Basel) supported Dr Berger. These funding sources had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. None of the authors has a conflict of interest with any manufacturer or distributor of omega-3 fatty acids. The presented data were part of an investigator-initiated Laxdale Ltd (now owned by Amarin Corporation) provided the study medication for free. None of the research centres received any financial support from Laxdale Ltd.